K36 Therapeutics

K36 Therapeutics

  • Founded: 2021
  • Location: Cambridge, MA
  • Employee range: 1 - 10
  • Clinical stage: Clin1
  • Therapy area: Multiple myeloma
  • Drug types: ONC
  • Lead product: KTX-1001
  • Product link: https://www.k36tx.com/our-science
  • Funding: $70M B Jun 2023; $30M A Dec 2021
  • Investors: Nextech Invest, Bristol Myers Squibb Company



Short description:

Inhibitor of the histone methyltransferase

Drug notes:

Contact us to add description: recruit@workinbiotech.com

Long description:

K36 Therapeutics is developing breakthrough epigenetic modulation therapies to treat multiple myeloma. Treatment options for multiple myeloma have improved in recent years, however, there are still many patients with high-risk mutations such as t(4;14) with poor prognosis and no effective treatment.This mutation leads to high expression of the MMSET gene. K36tx’s lead candidate, KTX-1001, is a selective inhibitor of the histone methyltransferase MMSET which is overexpressed in around 20% of multiple myeloma patients. K36tx is currently enrolling patients to begin KTX-1001 clinical testing.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com